Criteria for corticosteroid-refractory and ruxolitinib-refractory acute GVHD
| Criteria . |
|---|
| Corticosteroid-refractory acute GVHD |
| (1) Disease progression after 3 days of treatment with MP 2 mg/kg per day equivalent, |
| (2) Lack of improvement after 7 d of treatment with MP 2 mg/kg per day equivalent, |
| (3) Progression to a new organ after treatment with MP 1 mg/kg per day equivalent for skin and upper gastrointestinal GVHD, or |
| (4) Recurrence during or after a corticosteroid taper. |
| Ruxolitinib-refractory acute GVHD |
| (1) Progression of GVHD compared with baseline after ≥5 to 10 days of treatment with ruxolitinib, based either on objective increase in stage/grade or new organ involvement; |
| (2) Lack of improvement in GVHD (PR or better) compared with baseline after at least 14 days of treatment with ruxolitinib; or |
| (3) Loss of response, defined as objective worsening of GVHD determined by increase in stage, grade or new organ involvement at any time after initial improvement. |
| Criteria . |
|---|
| Corticosteroid-refractory acute GVHD |
| (1) Disease progression after 3 days of treatment with MP 2 mg/kg per day equivalent, |
| (2) Lack of improvement after 7 d of treatment with MP 2 mg/kg per day equivalent, |
| (3) Progression to a new organ after treatment with MP 1 mg/kg per day equivalent for skin and upper gastrointestinal GVHD, or |
| (4) Recurrence during or after a corticosteroid taper. |
| Ruxolitinib-refractory acute GVHD |
| (1) Progression of GVHD compared with baseline after ≥5 to 10 days of treatment with ruxolitinib, based either on objective increase in stage/grade or new organ involvement; |
| (2) Lack of improvement in GVHD (PR or better) compared with baseline after at least 14 days of treatment with ruxolitinib; or |
| (3) Loss of response, defined as objective worsening of GVHD determined by increase in stage, grade or new organ involvement at any time after initial improvement. |